Compare Goodyear Tire & Rubber Co (GT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Recursion Pharmaceuticals Inc — how do they compare? Goodyear Tire & Rubber Co trades at $7.22 (market cap $1.94B), while Recursion Pharmaceuticals Inc trades at $3.15 (market cap $1.75B). The key difference: Goodyear Tire & Rubber Co and Recursion Pharmaceuticals Inc are close in size by market cap, and Goodyear Tire & Rubber Co is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GT | RXRX | |
|---|---|---|
Market Cap | $1.94B | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.54 | $6.79 |
52-Week Low | $5.58 | $2.84 |
Enterprise Value | $9.25B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $6.66, up 0.3% with neutral technical signals. The stock shows mixed fundamentals with attractive valuation ratios (P/E 4.69, P/B 0.64) but negative profitability (ROE -52.56%, net margin -11.64%). Recent Q1 2026 earnings beat estimates despite a loss, while the company transitions to S&P SmallCap 600. Cash flow improved in 2025 with $46M net inflow, though revenue declined to $18.28B.
Outlook remains challenging with declining revenue and negative margins, though deep value metrics and analyst consensus target of $8.75 suggest upside potential. Key risks include persistent operational headwinds, weak tire demand, and high debt levels. The Goodyear Forward program and lunar tire contract provide strategic catalysts amid competitive pressures.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
